DBD Vietnam, a leading pharmaceutical and medical equipment company in Binh Dinh, made history as the first Vietnamese firm to produce cancer treatment medications in 2010.
The company’s current cancer treatment medications fall under chemotherapy drugs, while targeted therapy drugs are also in development. With a diverse portfolio of 40 products, 16 active ingredients, and two formulations, DBD boasts the largest market share in chemotherapy cancer drugs in Vietnam. Their products are available in most specialized hospitals and hospitals with oncology departments.
In addition, DBD’s antibiotic offerings (82 products, 37 active ingredients, and four formulations) and dialysis solutions are also key contributors to their success. According to a recent report by ACBS Securities Company, the hospital channel remains DBD’s primary sales avenue, despite significant contributions from the pharmacy channel. In the first quarter of 2025, hospital sales accounted for 67% of self-produced revenue, with pharmacies contributing the remaining.
DBD is gearing up with a range of new initiatives. The upgrade of their cancer drug manufacturing facility in Nhon Hoi Economic Zone to EU-GMP standards is expected to be completed by 2027. This will enable the company to bid for Group 2 drugs in hospital channels, a significant improvement from their current Group 4 status.
Additionally, DBD anticipates obtaining four registrations for targeted cancer pills in 2025, with potential market share gains starting in 2026. Moreover, the small-volume sterile drug manufacturing plant for injectable antibiotics, which broke ground in 2023, is in its final stages of construction, with QA-QC-R&D centers being prioritized for completion, and machinery already en route.
For 2025, DBD aims for net revenue of VND 2,000 billion, a 10.1% increase year-over-year, and pre-tax profit of VND 335 billion, up 3.1%. If achieved, these figures would represent new historical peaks for the company.
In the first quarter of 2025, DBD recorded a 15% year-over-year growth in net revenue, totaling VND 441 billion (with 95% attributed to self-produced revenue), driven by a 21% surge in hospital channel sales.
Net profit after tax witnessed a substantial 21% year-over-year increase, reaching VND 96 billion.
Looking ahead, DBD is committed to investing in high-standard production facilities while continuing to develop its current core product lines. They also intend to venture into first-generation generic drugs, high-tech, and specialty drugs in high demand for domestic production to replace imported medications.
The company is in discussions with potential investors to execute a plan to privately offer a 24.91% stake, targeting strategic partners with industry expertise rather than financial investors. Proceeds from this offering are intended to fund projects, including the small-volume sterile drug manufacturing plant and the non-betalactam OSD drug manufacturing facility.
In the stock market, DBD shares closed at VND 54,600 per share on June 13, 2025, marking a 30% increase from its low. The company’s market capitalization exceeded VND 5,100 billion.
